Mannkind CORP Form 4 insider transactions

MannKind Corp. Director James Samuel Shannon acquired 12,000 shares of common stock at $3.27 per share through the company's stock purchase plan, increasing his direct beneficial ownership to 64,635 shares.

MannKind Corp. Director Anthony C. Hooper acquired 35,000 shares of common stock at $3.27 per share through a company plan.

MannKind Corp's Chief Financial Officer, Christopher Prentiss, acquired 5,000 shares of common stock at $3.27 per share through an employee stock purchase plan.

MannKind Corp's CEO, Michael Castagna, increased his direct ownership of common stock and saw significant performance-based stock options vest.

MannKind Corp. Director Steven B. Binder saw 45,025 performance-based stock options vest on February 26, 2026.

MannKind Corporation's EVP, General Counsel, and Secretary, David Thomson, reported the vesting of 57,525 employee stock options following the achievement of performance milestones.

MannKind's Chief People & Workplace Officer, Stuart A. Tross, acquired common stock and saw significant employee stock options vest following performance milestones.

MannKind's Chief People & Workplace Officer, Stuart A. Tross, sold 47,006 shares of common stock for $6.33 per share under a pre-arranged 10b5-1 plan.

MannKind Corp's CEO, Michael Castagna, reported a charitable donation of 44,171 shares of common stock on December 24, 2025.

MannKind Corp's CEO and Director, Michael Castagna, sold 65,804 shares of common stock at an average price of $6.01 after exercising options.

MannKind Corp. CEO Michael Castagna executed a pre-planned sale of company stock following the exercise of employee stock options in December 2025.

MannKind Corp CEO Michael Castagna exercised stock options and subsequently sold 107,920 shares of common stock for a net gain.

David Thomson, EVP General Counsel & Secretary of MannKind Corp, exercised stock options and subsequently sold 147,780 shares under a Rule 10b5-1 plan.

MannKind Corp's EVP of Technical Operations, Sanjay R Singh, sold 18,777 shares of common stock for $5.03 per share under a pre-arranged 10b5-1 plan.

Mannkind Corp's Chief Medical Officer, Ajay Ahuja, was granted 318,200 restricted stock units with a four-year vesting schedule.

Sanjay R Singh, EVP Technical Operations at MannKind Corp, disposed of 17,071 common shares to cover income tax obligations from restricted stock unit vesting.

MannKind's Chief People & Workplace Officer, Stuart A. Tross, sold 47,000 shares of common stock for $5.34 per share under a pre-arranged 10b5-1 plan.

MannKind Corp's Chief People & Workplace Officer, Stuart A. Tross, acquired 12,755 shares of common stock at $3.92 per share.

MannKind Corp. Director Steven B. Binder reported the sale of 75,367 shares of common stock and the disposition of 19,383 shares for tax liability, reducing his direct beneficial ownership to 830,508 shares.

MannKind Corp's EVP Chief Medical Officer, Burkhard Blank, reported the disposition of 9,556 shares of common stock at $3.85 per share on July 15, 2025, related to tax liabilities from restricted stock unit vesting.

MannKind Corp's EVP of Technical Operations, Sanjay R Singh, reported the disposition of 15,450 common shares at $3.85 per share to cover tax liabilities related to restricted stock unit vesting.

MannKind Corp's CEO, Michael Castagna, disposed of 111,275 shares of common stock on July 15, 2025, to cover tax liabilities related to the vesting of restricted stock units.

MannKind Corp's Chief People & Workplace Officer, Stuart A. Tross, reported the disposition of 28,057 shares of common stock at $3.85 per share on July 15, 2025, related to the vesting of restricted stock units, while still beneficially owning 1,066,258 shares.

MannKind Corp's EVP, General Counsel & Secretary, David Thomson, reported the disposition of shares for tax purposes and a sale of common stock under a pre-arranged Rule 10b5-1 plan.

MannKind Corp's EVP Operations, Lauren Sabella, reported the disposition of 11,896 common shares at $3.85 each to cover tax liabilities related to restricted stock unit vesting, while her total beneficial ownership stands at 349,841 shares.

MannKind Corporation's Chief Financial Officer, Christopher B. Prentiss, reported a disposition of shares for tax withholding purposes related to restricted stock unit vesting, alongside an acquisition of shares through an Employee Stock Purchase Plan.

MannKind Corp (MNKD) has granted 1,000,000 performance-based restricted stock units to Dominic Marasco, President of its Endocrine Business Unit, aligning executive incentives with future net sales targets.

Steven B. Binder, a Director at MannKind Corp, sold 64,085 shares of common stock on June 10, 2025, under a pre-established Rule 10b5-1 trading plan.

MannKind Corporation's EVP Chief Medical Officer, Burkhard Blank, reported the disposition of 15,630 shares of common stock at $4.12 per share to cover tax liabilities related to the vesting of restricted stock units.

MannKind Corp's EVP Chief Medical Officer, Burkhard Blank, filed an amended Form 4 to correct the reported amount of common stock beneficially owned.